Novel tumor marker index combining carcinoembryonic antigen and carbohydrate antigen 19-9: New prognostic factor for metastatic colorectal cancer

Basit Öğe Kaydı
dc.contributor.authorİlhan, Y
dc.contributor.authorBalçık, OY
dc.contributor.authorGüzel, HG
dc.contributor.authorÖnder, AH
dc.contributor.authorDemir, B
dc.contributor.authorBaşer, MN
dc.contributor.authorKaradağ, I
dc.contributor.authorÖzbay, MF
dc.contributor.authorGenç, TB
dc.contributor.authorUzuntaş, S
dc.contributor.authorPoyrazoğlu, O
dc.contributor.authorBeypınar, İ
dc.contributor.authorErgün, Y
dc.contributor.authorÖztürk, B
dc.date.accessioned2026-03-31T13:21:03Z
dc.date.available2026-03-31T13:21:03Z
dc.date.issued2025
dc.description.abstractBACKGROUND Metastatic colorectal cancer (mCRC) is a global health challenge with a poor prognosis. Prognostic markers are critical for survival prediction. AIM To evaluate a novel tumor marker index (TMI) combining carcinoembryonic antigen and carbohydrate antigen 19-9. METHODS This multicenter, retrospective study measured baseline carcinoembryonic antigen and carbohydrate antigen 19-9 levels to calculate a TMI as the geometric mean of values normalized to their upper limits of normal. Receiver operating characteristic curve analysis assessed TMI's prognostic accuracy, and patients were stratified into high-TMI (>= 1.39) and low-TMI (< 1.39) groups. The primary endpoint was overall survival (OS), with progression-free survival and treatment response as secondary endpoints. RESULTS The study included 305 mCRC patients with a median follow-up of 22.9 months. The median OS for high-TMI patients was 29.5 months, significantly lower than the 45.6 months observed in the low-TMI group (P = 0.02). The 2-year OS rates for the high- and low-TMI groups were 59.4% and 72.9%, respectively. Median progression-free survival was also shorter for the high-TMI group (14.0 vs 16.0 months, P = 0.84). High TMI is an independent prognostic factor for worse OS. CONCLUSION TMI is a simple, cost-effective prognostic tool for mCRC, with high TMI associated with poorer survival outcomes.
dc.identifier.doi10.4251/wjgo.v17.i5.104341
dc.identifier.issn1948-5204
dc.identifier.issue5
dc.identifier.pmid40487947
dc.identifier.urihttp://dx.doi.org/10.4251/wjgo.v17.i5.104341
dc.identifier.urihttps://hdl.handle.net/11491/9498
dc.identifier.volume17
dc.identifier.wosWOS:001498719600023
dc.language.isoen
dc.publisherBAISHIDENG PUBLISHING GROUP INC
dc.relation.ispartofWORLD J GASTRO ONCOL
dc.subjectColorectal cancer biomarkers
dc.subjectMetastatic colorectal cancer
dc.subjectCarcinoembryonic antigen
dc.subjectCarbohydrate antigen 19-9
dc.subjectTumor marker index
dc.titleNovel tumor marker index combining carcinoembryonic antigen and carbohydrate antigen 19-9: New prognostic factor for metastatic colorectal cancer
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu